Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
RenJi Hospital
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female, Aged ≥18 and ≤70 years
Histologically confirmed invasive HER2 positive breast cancer, early disease(Stage ⅡA-Ⅲ)
Subjects with at least one evaluable lesion
ECOG 0-1
Adequate organ function
You may not be if
Metastatic disease (Stage IV)
Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
Treated or treating with T-DM1, lapatinib and neratinib before study entry
History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation
Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial
Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test. Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study
Clareo Health | Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
